Label Expansion for Astellas Drug - Analyst Blog

By
A A A

Astellas Pharma Inc. ( ALPMY ) recently announced the approval of Prograf in Japan for an additional indication.

Prograf is now approved for interstitial pneumonia associated with polymyositis/dermatomyositis. It was granted orphan drug status by the Ministry of Health, Labor and Welfare (MHLW).

Prograf is already available in Japan to prevent organ rejection in transplant recipients, the prevention of rejection in bone marrow transplant recipients, the treatment of myasthenia gravis, the treatment of rheumatoid arthritis in patients who respond insufficiently to existing therapies, the treatment of moderate/severe refractory (steroid resistance and steroid dependency) ulcerative colitis and also for the treatment of lupus nephritis.


Prograf generated global sales of 161.7 billion yen in 2012, including 49.4 billion yen from Japan, 31.4 billion yen from the Americas, 57.5 billion yen from Europe and 18.9 billion yen from Asia.

Prograf is also available in the US to prevent organ rejection in patients who have had a kidney, liver or heart transplant.

US patents for Prograf expired in Apr 2008 and Prograf patents in major European countries expired in Jun 2009.

Currently, Prograf faces generic competition in the US. Generic versions of Prograf were launched by companies like Mylan Inc ( MYL ), Dr. Reddy's Laboratories Ltd. ( RDY ) and Actavis Inc. ( ACT ).

Astellas carries a Zacks Rank #4 (Sell). Astellas recently received a complete response letter (CRL) for tivozanib from the US Food and Drug Administration (FDA). A New Drug Application (NDA) for tivozanib seeking approval for the treatment of patients with advanced renal cell carcinoma (RCC) was submitted in Sep 2012. The FDA has informed that the NDA is not approvable in its present form.

The generic players, Mylan and Dr. Reddy's, look attractive with a Zacks Rank #2 (Buy).



ACTAVIS INC (ACT): Free Stock Analysis Report

ASTELLAS PHARMA (ALPMY): Get Free Report

MYLAN INC (MYL): Free Stock Analysis Report

DOCTOR REDDYS (RDY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ACT , ALPMY , CRL , MYL , RDY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Avatars of the Luxe Life
Avatars of the Luxe Life            

Stocks

Referenced

67%
100%
75%
100%

Most Active by Volume

49,730,367
  • $6.77 ▲ 11.72%
31,083,778
  • $6.93 ▲ 3.43%
30,795,295
  • $7.755 ▲ 1.51%
29,137,926
  • $17.385 ▲ 0.72%
24,291,896
  • $111.0299 ▲ 1.48%
23,868,659
  • $44.415 ▲ 7.91%
23,128,596
  • $103.38 ▲ 1.55%
18,271,193
  • $7.795 ▲ 8.41%
As of 12/18/2014, 11:46 AM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com